Modality
mAb
MOA
STINGag
Target
Aβ
Pathway
Sphingolipid
MG
Development Pipeline
Preclinical
~Jan 2018
→ ~Apr 2019
Phase 1
~Jul 2019
→ ~Oct 2020
Phase 2
Jan 2021
Phase 2Current
NCT05912201
1,128 pts·MG
2021-01→TBD·Active
1,128 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
2021
P2/3
Active
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05912201 | Phase 2/3 | MG | Active | 1128 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-7550 | Pfizer | Phase 3 | Aβ | |
| Sotovorutinib | Pfizer | Approved | Aβ | |
| RHH-5389 | Roche | Preclinical | RET | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| Datobrutinib | Sanofi | Phase 3 | Aβ | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 |